Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Faraday Pharmaceuticals is raising $52,800,000.00 in new funding. Sources indicate as part of senior management Chief Financial and Business Officer, Brian Blackman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Faraday Pharmaceuticals
Faraday Pharmaceuticals is a biopharmaceutical company pioneering the use of specific, reduced forms of natural elements elemental reducing agents to improve quality of life after acute, critical illness. While life expectancy has increased, so has the number of years that people live in poor health. A major contributor to decreased quality of life is associated with muscle loss following illnesses such as a heart attack or other emergency health crises. Our lead therapeutic candidate, FDY-5301, is being evaluated for its potential to minimize damage to cardiac and skeletal muscle.

To learn more about Faraday Pharmaceuticals, visit http://faradaypharma.com/

Contact:
Brian Blackman, Chief Financial and Business Officer
206-492-5310
https://www.linkedin.com/in/brian-blackman-178a41/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved